IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification

IMUNON, Inc. announced that the Independent Data Monitoring Committee has recommended the continuation of its Phase 2 minimal residual disease (MRD) study of IMNN-001 without modification, citing no new safety signals. The study, which assesses the safety and tolerability of IMNN-001 in combination with standard chemotherapy and bevacizumab for advanced ovarian cancer, has shown a differentiated safety profile with no observed serious adverse events. This recommendation follows positive preliminary data reported in July, indicating deeper anti-tumor activity and immune activation.